IUB® SEAD®
GLOBAL ENDOMETRIAL ABLATION MARKET GAME CHANGER
The IUB® SEAD® (Spherical Endometrial Ablation Device) – currently in Phase II Clinical Studies – offers a disposable, point of care therapy for abnormal uterine bleeding (AUB) and/or heavy menstrual bleeding – a far more comfortable and cost effective alternative for hundreds of thousands of women per year who opt to increase their quality of life.
14 – 25% of women
of reproductive age
are affected by AUB
indirect economic
costs of AUB in the US
for OBGYN visit
heavy periods
disruptive to sex life
exhausted when
period is heaviest
42% of women suffer
from depression
due to heavy periods
The Solution - IUB® SEAD®
The IUB® SEAD® is an innovative intrauterine drug delivery technology for women with abnormal uterine bleeding and/or heavy menstrual bleeding. The current standard of care (global endometrial ablation) is considered invasive, burdensome, debilitating, and costly and may result in uterine wall adhesions and even a hysterectomy.
Current global ablation technologies currently in use require expensive capital equipment, extensive physician training, general anesthesia & hospitalization and cause high indirect costs and usually pain to women.
The IUB® SEAD® is a market game-changer through simplicity, cost-effectiveness, and new and innovative yet gentle “substance-derived ablation” technology. The IUB® SEAD® is nearly pain-free2 and efficacious to reduce bleeding and increase the quality of life.
THE IUB® SEAD® VALUE PROPOSITION:
- Highly cost effective: <1/2 compared to current treatments.
- Less invasive for women: pain-free2 and no need for hospitalization or general anesthesia
- A once-and-done in-office procedure: as easy, quick and painless as an IUD insertion.
- As simple, easy, quick and painless as an IUD insertion.
- Overcomes problems of uterine size and/or shape limitations.
THE SEAD™
IUB® SEAD® Scientific Publications
IUB® SEAD® highlighted in the 2021 FIGO World Congress of Gynaecology and Obstetrics as an Oral Scientific Presentation along with a Spotlight.
The data presented at the 2021 FIGO World Congress on OCON’s IUB® SEAD® (Spherical Endometrial Ablation Device) shows over 80% reduction in bleeding with 95% of women reporting quality of life satisfaction.” Prof. Sergio Haimovich, CMO.
The SEAD™
The IUB® SEAD® is a market game-changer through simplicity, cost-effectiveness, and new and innovative yet gentle “substance-derived ablation” technology.
Phase I Clinical Studies have successfully demonstrated safety3. Phase II Clinical Studies are currently ongoing.
The IUB® SEAD® has the potential of becoming a strong and attractive choice of therapy in the worldwide GEA market through its simplicity, cost effectiveness and new and innovative yet gentle “substance-based Ablation” technology.
2 ongoing Phase II Clinical Studies, OCON Medical Ltd.
3 Phase I Clinical Study, OCON Medical Ltd.
